Lack of support for bexarotene as a treatment for Alzheimer's disease.

Eugene O'Hare, Ross Jeggo, Eun-Mee Kim, Bridgeen Barbour, Jean-Sebastian Walczak, Philip Palmer, Taylor Lyons, Deaglan Page, Donncha Hanna, Jolyon R. Meara, David Spanswick, Jian-Ping Guo, Edith G. McGeer, Patrick L. McGeer, Peter Hobson

Research output: Contribution to journalArticle

19 Citations (Scopus)
310 Downloads (Pure)
Original languageEnglish
Pages (from-to)124-130
Number of pages7
JournalNeuropharmacology
Volume100
Early online date27 May 2015
Publication statusPublished - Jan 2016

Cite this

O'Hare, E., Jeggo, R., Kim, E-M., Barbour, B., Walczak, J-S., Palmer, P., Lyons, T., Page, D., Hanna, D., Meara, J. R., Spanswick, D., Guo, J-P., McGeer, E. G., McGeer, P. L., & Hobson, P. (2016). Lack of support for bexarotene as a treatment for Alzheimer's disease. Neuropharmacology, 100, 124-130.